PriceTargets.com logo

Cardio Diagnostics - CDIO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.00
  • Forecasted Upside: 135.29%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.85 As of 12/17/2024 01:00 AM ET
▼ -0.27 (-24.11%)

This chart shows the closing price for CDIO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cardio Diagnostics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CDIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CDIO

Analyst Price Target is $2.00
▲ +135.29% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Cardio Diagnostics in the last 3 months. The average price target is $2.00, with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a 135.29% upside from the last price of $0.85.

This chart shows the closing price for CDIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Cardio Diagnostics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/18/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/27/2024BenchmarkReiterated RatingSpeculative Buy ➝ Speculative Buy$2.00 ➝ $2.00
6/6/2024BenchmarkBoost TargetSpeculative Buy ➝ Speculative Buy$1.35 ➝ $2.00
4/19/2024BenchmarkLower TargetSpeculative Buy ➝ Speculative Buy$4.00 ➝ $1.35
5/22/2023Northland SecuritiesInitiated CoverageOutperform
11/4/2022BenchmarkLower Target$8.00
(Data available from 12/18/2019 forward)

News Sentiment Rating

0.45 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/22/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/20/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Cardio Diagnostics logo
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Read More

Today's Range

Now: $0.85
Low: $0.78
High: $1.10

50 Day Range

MA: $0.39
Low: $0.20
High: $1.52

52 Week Range

Now: $0.85
Low: $0.19
High: $3.56

Volume

11,599,857 shs

Average Volume

2,172,373 shs

Market Capitalization

$34.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

4.59

Frequently Asked Questions

What sell-side analysts currently cover shares of Cardio Diagnostics?

The following equities research analysts have issued stock ratings on Cardio Diagnostics in the last twelve months: Benchmark Co..
View the latest analyst ratings for CDIO.

What is the current price target for Cardio Diagnostics?

0 Wall Street analysts have set twelve-month price targets for Cardio Diagnostics in the last year. Their average twelve-month price target is $2.00, suggesting a possible upside of 135.3%. Benchmark Co. has the highest price target set, predicting CDIO will reach $2.00 in the next twelve months. Benchmark Co. has the lowest price target set, forecasting a price of $2.00 for Cardio Diagnostics in the next year.
View the latest price targets for CDIO.

What is the current consensus analyst rating for Cardio Diagnostics?

Cardio Diagnostics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CDIO will outperform the market and that investors should add to their positions of Cardio Diagnostics.
View the latest ratings for CDIO.

What other companies compete with Cardio Diagnostics?

Other companies that are similar to Cardio Diagnostics include Bright Minds Biosciences, Corbus Pharmaceuticals, Innate Pharma, Sagimet Biosciences and Actuate Therapeutics. Learn More about companies similar to Cardio Diagnostics.

How do I contact Cardio Diagnostics' investor relations team?

The company's listed phone number is 302-281-2147 and its investor relations email address is [email protected]. The official website for Cardio Diagnostics is cardiodiagnosticsinc.com. Learn More about contacing Cardio Diagnostics investor relations.